الفهرس | Only 14 pages are availabe for public view |
Abstract Tizanidine hydrochloride (TZN), is a skeletal muscle relaxant, clinically used {u200E}for the symptomatic treatment of muscle stiffness and spasms resulting {u200E}from multiple sclerosis, injury or disease of the spinal cord. Its {u200E}principal site of action is the spinal cord, as a centrally acting alpha 2-{u200E}receptor agonist which regulates the relaxant effects on skeletal muscles{u200E}.The aim of this thesis was to formulate novel vesicular carriers for TZN to be administered {u200E}transdermally in an attempt to enhance its bioavailability.Two types of {u200E}vesicular formulations have been investigated as carriers, namely ; bilosomes {u200E}and aspasomes. Thin film hydration method was adopted in this study to formulate TZN {u200E}loaded bilosomes.TZN bilosomes were prepared using different types of {u200E}non-ionic span (sp) surfactants (sp20, sp40, sp60) with different molar {u200E}ratio with respect to cholesterol (CH) (3:7,1:1,7:3) in addition to different {u200E}amount of sodium deoxycholate (SDC) comprising the key component of {u200E}bilosomes (5, 10, 20 mg). A 3-factor, 3-level full factorial design was {u200E}generated in the current study to develop and optimize the transdermal {u200E}bilosomes of TZN |